Horgan, who began working in the drug development sector in 1997 and moved to the US in 2000, began working with Firecrest in 2009 to establish its US operations and globalise the business.
Horgan has held several management positions in the healthcare clinical research organisation (CRO) sector, most notably at MDS Pharma Services as group vice president, late stage development, and at Covance as corporate senior vice president and president, clinical development. His broad experience makes him suited to build on the strong foundations that Firecrest has established in Europe and the US.
Gerard Ryan, chairman of Firecrest, said: ‘The 10 years that Alan Horgan has spent working with large CROs, coupled with his deep understanding of the challenges facing investigative sites, will undoubtedly lead Firecrest in its quest to drive site performance in complex clinical trials. We are happy to have him on board.’
Under Horgan’s leadership, Firecrest will continue to expand its highly structured and integrated solutions on a global basis in Phase II, III, and IV clinical studies.
Firecrest’s products and services help investigators run complex trials by improving compliance, consistency, and quality of execution of all study-related procedures and activities conducted by investigator site staff and monitoring teams.
